Grufity logo
Grufity logo

Latest Frazier Life Sciences Management, L.P. Stock Portfolio

$4.59Billion | No. of Holdings #41

Frazier Life Sciences Management, L.P. Performance

2026 Q2+17.86%
YTD+22.19%
2025+72.11%

About Frazier Life Sciences Management, L.P. and 13F Hedge Fund Stock Holdings

On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Frazier Life Sciences Management, L.P. reported an equity portfolio of $4.6 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Frazier Life Sciences Management, L.P. are MIRM, NAMS, ERAS. The fund has invested 19.6% of it's portfolio in MIRUM PHARMACEUTICALS INC and 13.3% of portfolio in NEWAMSTERDAM PHARMA COMPANY. <br><br> The fund managers got completely rid off KALVISTA PHARMACEUTICALS INC (KALV), REVOLUTION MEDICINES INC (RVMD) and AGIOS PHARMACEUTICALS INC (AGIO) stocks. They significantly reduced their stock positions in BRIDGEBIO PHARMA INC (BBIO) and TREVI THERAPEUTICS INC (TRVI). Frazier Life Sciences Management, L.P. opened new stock positions in PARABILIS MEDICINES INC, ACHIEVE LIFE SCIENCE INC (ACHV) and DESIGN THERAPEUTICS INC (DSGN). The fund showed a lot of confidence in some stocks as they added substantially to ALLOGENE THERAPEUTICS INC (ALLO), ASCENDIS PHARMA A/S (ASND) and AURA BIOSCIENCES INC (AURA).
Frazier Life Sciences Management, L.P. Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$4.59Billion
  as of Aug 14, 2026

Frazier Life Sciences Management, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that Frazier Life Sciences Management, L.P. made a return of 17.86% in the last quarter. In trailing 12 months, it's portfolio return was 108.59%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
parabilis medicines inc52,572,400
achieve life science inc49,724,900
design therapeutics inc26,188,600
shattuck labs inc26,025,000
kailera therapeutics inc24,233,000
relay therapeutics inc19,003,600
New stocks bought by Frazier Life Sciences Management, L.P.

Additions

Ticker% Inc.
allogene therapeutics inc491
ascendis pharma a/s68.87
aura biosciences inc39.22
mannkind corp11.86
maze therapeutics inc10.2
lexeo therapeutics inc9.04
newamsterdam pharma company6.76
erasca inc1.22
Additions to existing portfolio by Frazier Life Sciences Management, L.P.

Reductions

Ticker% Reduced
bridgebio pharma inc-55.1
trevi therapeutics inc0.00
Frazier Life Sciences Management, L.P. reduced stake in above stock

Sold off

Ticker$ Sold
kalvista pharmaceuticals inc-99,867,100
agios pharmaceuticals inc-42,493,200
revolution medicines inc-65,710,500
Frazier Life Sciences Management, L.P. got rid off the above stocks

Sector Distribution

Frazier Life Sciences Management, L.P. has about 65.8% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare65.8
Others34.2

Market Cap. Distribution

Frazier Life Sciences Management, L.P. has about 7.2% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • UNALLOCATED
  • SMALL-CAP
  • LARGE-CAP
Category%
MID-CAP46.8
UNALLOCATED34.2
SMALL-CAP11.7
LARGE-CAP7.2

Stocks belong to which Index?

About 63.2% of the stocks held by Frazier Life Sciences Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
Index%
RUSSELL 200063.2
Others36.8
Top 5 Winners (%)%
mbx biosciences inc
84.9 %
EOLS
evolus inc
68.9 %
MNKD
mannkind corp
67.3 %
TRVI
trevi therapeutics inc
56.3 %
ALKS
alkermes plc
48.2 %
Top 5 Winners ($)$
MIRM
mirum pharmaceuticals inc
189.6 M
mbx biosciences inc
168.6 M
TRVI
trevi therapeutics inc
66.8 M
KRYS
krystal biotech inc
54.6 M
ERAS
erasca inc
53.1 M
Top 5 Losers (%)%
lexeo therapeutics inc
-18.3 %
VALN
valneva se
-16.3 %
TARS
tarsus pharmaceuticals inc
-10.3 %
ALLO
allogene therapeutics inc
-9.2 %
IBIO
ibio inc
-7.9 %
Top 5 Losers ($)$
TARS
tarsus pharmaceuticals inc
-5.3 M
lexeo therapeutics inc
-5.0 M
ALLO
allogene therapeutics inc
-4.7 M
PHAT
phathom pharmaceuticals inc
-3.2 M
VALN
valneva se
-2.3 M

Frazier Life Sciences Management, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Frazier Life Sciences Management, L.P.

Frazier Life Sciences Management, L.P. has 41 stocks in it's portfolio. About 73.6% of the portfolio is in top 10 stocks. TARS proved to be the most loss making stock for the portfolio. MIRM was the most profitable stock for Frazier Life Sciences Management, L.P. last quarter.

$4.59BTotal Value
44.00Positions
14 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of Frazier Life Sciences Management, L.P., last reported on 14 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ASND
Ascendis Pharma A/S

Ascendis Pharma A/S

ASND
Frazier Life Sciences Management, L.P.'s holding in Ascendis Pharma A/S over time
1.31%225,155
$60.05M
1.31%
increased 68.87 percentadded
AUTL
Autolus Therapeutics Ltd

Autolus Therapeutics Ltd

AUTL
Frazier Life Sciences Management, L.P.'s holding in Autolus Therapeutics Ltd over time
0.16%4,447,910
$7.12M
0.16%
unchanged 0 percentunchanged
IMCR
Immunocore Hldgs Plc

Immunocore Hldgs Plc

IMCR
Frazier Life Sciences Management, L.P.'s holding in Immunocore Hldgs Plc over time
0.34%484,782
$15.39M
0.34%
unchanged 0 percentunchanged